Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
AssigneeThe Research Foundation of State University of New York
InventorStanley Zucker
Life of this patent
Estimating the term…
Abstract
Diagnostic agents and methods for detecting the presence of metastatic activity in biological samples such as plasma are disclosed. The agent and method preferably immunologically detect matrix metalloproteinases in complexed form with endogenous inhibitors of MMP's. A kit for detecting the metalloproteinases is also disclosed.
Claims11
A method of screening for the presence of metastic disease in a biological sample, comprising:
- a) contacting a biological sample with a first immunologically responsive substance which specifically binds a molecule selected from a first group consisting of matrix metalloprateinase, matrix metalloproteinase complexed with tissue inhibitor of metalloproteinase, and break down products thereof;
- or a second group consisting of tissue inhibitor of metalloproteinase, tissue inhibitor of metalloproteinase complexed with matrix metalloproteinase and break down products thereof;
- b) isolating a product having said first immunologically responsive substance that may be bound to said biological sample;
- c) contacting said product with a second detactably labled immunologically responsive substance which specifically binds a molecule selected from said first group or from said second group wherein, if said first immunologically responsive substance is selected from said first group then said second immunologically responsive substance is selected from said second group, or if said first immunologically responsive substance is selected from said second group then said second immunologiclly responsive substance is selcted from said first group;
- d) detecting said second detectably labeled immunologically responsive substance;
- e) quantifying an amount of said second detectably labeled immunologically responsive substance detected in step d);
- f) comparing said amount with a reference standard of metastatic disease to provide a quantitative value;
- and
- g) correlating said quantitative value to metastatic disease in said biological sample.
The method of claim 11, whrein quantifying said amount of said detectably labeled immunologically responsive substance recited in step e) is accomplished utilizing a quantification method selected from the group consisting of quantifying electro-magnetic absorbance and radioactive emissions.
A method of screening for the presence of metastatic disease in a biological sample, comprising:
- a) contacting a biological sample with a detectably labeled immunologically responsive substance which specifically binds a matrix metalloproteinase-tissue inhibitor of metalloproteinase complex and break down products thereof;
- b) detecting said detectably labeled immunologically responsive substance bound to said biological sample;
- c) quantifying an amount of said detectably labeled immunologically responsive substance detected in step b);
- d) comparing said amount with a reference standard of metastatic disease to provide a quantative value;
- and
- e) correlating said quantitative value to metastatic disease in said biological sample.
Dependencies are inferred from the claim text.